Compare Torrent Pharma with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs NEULAND LABS - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA NEULAND LABS TORRENT PHARMA/
NEULAND LABS
 
P/E (TTM) x 37.0 64.1 57.8% View Chart
P/BV x 9.4 4.8 193.3% View Chart
Dividend Yield % 0.6 0.1 871.7%  

Financials

 TORRENT PHARMA   NEULAND LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
NEULAND LABS
Mar-20
TORRENT PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs1,964754 260.6%   
Low Rs1,245247 503.4%   
Sales per share (Unadj.) Rs453.4594.5 76.3%  
Earnings per share (Unadj.) Rs25.812.6 204.1%  
Cash flow per share (Unadj.) Rs62.337.0 168.3%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.10.4 265.1%  
Book value per share (Unadj.) Rs279.2553.4 50.5%  
Shares outstanding (eoy) m169.2212.83 1,318.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.50.8 420.3%   
Avg P/E ratio x62.239.6 157.1%  
P/CF ratio (eoy) x25.813.5 190.5%  
Price / Book Value ratio x5.70.9 635.5%  
Dividend payout %65.915.8 416.5%   
Avg Mkt Cap Rs m271,5136,421 4,228.7%   
No. of employees `00013.61.3 1,060.7%   
Total wages/salary Rs m14,0381,236 1,136.2%   
Avg. sales/employee Rs Th5,642.65,949.4 94.8%   
Avg. wages/employee Rs Th1,032.4963.8 107.1%   
Avg. net profit/employee Rs Th320.9126.4 253.8%   
INCOME DATA
Net Sales Rs m76,7287,627 1,006.0%  
Other income Rs m57139 1,468.5%   
Total revenues Rs m77,2997,666 1,008.3%   
Gross profit Rs m19,8311,019 1,946.3%  
Depreciation Rs m6,177313 1,974.7%   
Interest Rs m5,038216 2,335.1%   
Profit before tax Rs m9,187529 1,736.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,254367 341.4%   
Profit after tax Rs m4,363162 2,691.9%  
Gross profit margin %25.813.4 193.5%  
Effective tax rate %13.669.4 19.7%   
Net profit margin %5.72.1 267.6%  
BALANCE SHEET DATA
Current assets Rs m50,3755,152 977.8%   
Current liabilities Rs m51,6533,576 1,444.3%   
Net working cap to sales %-1.720.7 -8.1%  
Current ratio x1.01.4 67.7%  
Inventory Days Days92105 87.6%  
Debtors Days Days6891 75.2%  
Net fixed assets Rs m83,6483,969 2,107.8%   
Share capital Rs m846129 656.0%   
"Free" reserves Rs m46,3976,971 665.6%   
Net worth Rs m47,2447,100 665.4%   
Long term debt Rs m39,129774 5,057.4%   
Total assets Rs m141,20912,310 1,147.1%  
Interest coverage x2.83.5 81.8%   
Debt to equity ratio x0.80.1 760.0%  
Sales to assets ratio x0.50.6 87.7%   
Return on assets %6.73.1 216.9%  
Return on equity %9.22.3 404.5%  
Return on capital %12.39.5 130.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,1035,187 426.1%   
Fx outflow Rs m5,5221,593 346.7%   
Net fx Rs m16,5813,594 461.4%   
CASH FLOW
From Operations Rs m17,981573 3,135.8%  
From Investments Rs m-2,413-487 495.6%  
From Financial Activity Rs m-13,145-55 23,986.3%  
Net Cashflow Rs m2,38033 7,301.2%  

Share Holding

Indian Promoters % 71.5 36.3 197.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 63.7 11.0%  
FIIs % 12.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 63.7 13.8%  
Shareholders   26,511 12,705 208.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS